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Abstract
The mouse uncoupling protein 1 gene (Ucpl) is expressed specifically in brown adipose 
tissue and its transcription is increased by cold exposure. We have analyzed the 
transcriptional control of this gene through deletion analysis of the upstream untranslated 
regions of Ucpl. Mutated minigene constructs were microinjected into mouse pronuclei 
to generate transgenic mice. Positive transgenic founders were crossed with Balb/cByJ 
+/+ mice to generate F] offspring heterozygous for the transgene, which were then 
examined for tissue-specific and cold inducible expression of the minigenes by northern 
analysis. Protein-DNA interactions at putuative regulatory sites were also explored 
through in vitro gel shift assays of the promoter and enhancer regions. We found that the 
sequence between -2,581 and -2,335 bp of the enhancer region is critical for the 
expression of Ucpl. We also discovered that the region located between -991 and -230 
bp does not play a major role in Ucpl expression. We found that nuclear factor-1 does 
not play a regulatory role at -166 bp in the promoter region. It was also observed that 
CCAAT enhancer binding protein does not interact with the 5’ flanking region at -2,450
Table of Contents
Abstract............................................................................................................................. iii
Table of Contents..............................................................................................................iv
List of Figures.................................................................................................................... vi
List of Tables......................................................................................................................viii
Acknowledgments............................................................................................................ ix
1. Introduction...................................................................................................................1
1.1 Ucpl Gene Regulation...................................................................................2
1.2 Current Research............................................................................................. 5
2. Materials and Methods.................................................................................................8
2.1 Animal Treatment........................................................................................... 8
2.2 RNA Isolation and Northern Blot Analysis................................................. 8
2.3 Nuclear Extract Isolation and Gel Mobility Shift Assay............................ 9
3. Results.............................................................................................................................10
3.1 Cold Exposed and Tissue-specific Northern Blot Analysis
of the Transgenic Lines......................................................................................... 10
3.2 Analysis of the Gel Shifts from the Enhancer Region..................................12
3.3 Analysis of the Gel Shifts from the Promoter Region.................................. 14
4. Discussion.......................................................................................................................16
4.1 C/EBP andNF-1 Effects on Ucpl Expression..........................................  16
iv
4.2 Nuclear Factors Bind to Additional Footprinted Regions In vitro  17
4.3 Transgenic Analysis of the Promoter, Enhancer and Silencer Regions......19
5. References................................................................................................................22
v
List of Figures
Figure 1. A map of the transgenic constructs............................................................. 28
Figure 2. Map of in vivo footprinting performed by Chen, 1996............................ 29
Figure 3. Cold exposed northern blot analysis of Ucpltgl m RN A .................. 30
Figure 4. Tissue-specificity northern blot analysis of UcpligX m RNA.....................31
Figure 5. Cold exposed northern blot analysis of Ucp]tgil m RN A ........... 32
Figure 6 . Cold exposed northern blot analysis of Ucpltg3 2 m RN A ........... 33
Figure 7. Tissue-specificity northern blot analysis of Ucpllg32 m RN A...................34
Figure 8 . Cold exposed northern blot analysis of Ucpltg4 m RN A ............................35
Figure 9. Tissue-specificity northern blot analysis of Ucpltg4 m RN A .....................36
Figure 10. Cold exposed northern blot analysis of Ucpltg6 m RN A ..........................37
Figure 11. Tissue-specificity northern blot analysis of Ucpltg6 m RN A...................38
Figure 12. Gel shift assay of the enhancer region between -2,586 and -2,547 bp.. 39
Figure 13. Gel shift assay of the enhancer region between -2,552 and -2,513 bp...40
Figure 14. Gel shift assay of the enhancer region between -2,450 and -2,411 bp. ..41
Figure 15. Gel shift assay of the enhancer region between -2,416 and -2,377 bp.. 42
Figure 16. Gel shift competition assay of C/EBP........................................................43
Figure 17. Gel shift assay of the promoter region between -184 and -145 bp 44
Figure 18. Gel shift assay of the promoter region between -164 and -125 bp 45
Figure 19. Gel shift competition assay of NF-1
List of Tables
Table 1. List of oligonucleotides used in gel shift analysis 
Table 2. Abbreviation l is t ....................................................
Acknowledgments
I would like to thank my advisor Dr. Bert Boyer, for his help and encouragement 
throughout my studies. I would like to thank my committee members, Dr. Lawrence 
Duffy and Dr. Gerald Plumley. I thank my colleagues Jamie Barger, Jason Knight and 
Ruth Stafford.
1. Introduction
Uncoupling protein 1 (UCP1) is a 32 icDa mitochondrial inner membrane protein that has 
six transmembrane domains (Nicholls and Locke, 1984). UCP1 functions as a fatty acid 
coupled proton transporter (Garlid et al., 1998). UCP1 dissipates the proton gradient by 
uncoupling substrate oxidation from ATP synthesis. Dissipation of the proton gradient 
produces heat by a process known as non-shivering thermogenesis. The activity of UCP1 
is inhibited by purine nucleotides binding on the cytosolic side of the mitochondrial inner 
membrane, resulting in inhibition of its transport function (Gonzalez-Barroso et al.,
1998). Fatty acids increase UCP1 activity either by serving as a fatty acid anion 
transporter or by acting as a prosthetic group of UCP1 (Gonzalaez-Barroso et al., 1998). 
UCP1 mediated non-shivering thermogenesis is unique to brown adipose tissue (BAT). 
Although UCP1 is only found in BAT, several other uncoupling proteins have been 
identified in various tissues of both rodents and humans. UCP2 is present in a large 
number of human tissues, with highest levels in skeletal muscle and white adipose tissue 
(WAT) (Fleury et al., 1997). UCP3 is abundant in skeletal muscle and BAT and is 
regulated by diet, thyroid hormone, p3-adrenergic agonists and leptin, suggesting a role in 
regulation of energy balance (Gong et al., 1997). UCP4 is a brain specific UCP homolog 
(Mao et al., 1999). Another uncoupling protein homolog known as brain mitochondrial 
carrier protein-1 (BMCP1), has been found in the central nervous system and at much 
lower levels in peripheral tissues (Sanchis et al., 1998). All of these proteins are 
structurally related to UCP1, but are expressed in diverse tissues and may be uniquely
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regulated (Denjean et al., 1999; Carmona et al., 1998). Due to the recent discovery of 
these proteins, we know very little about their gene-regulatory mechanisms. Therefore, 
elucidation of the uncoupling protein 1 {Ucpl) gene regulation in BAT should provide 
meaningful baseline data for comparison to the remaining Ucp homologs.
BAT thermogenesis has two functions: to maintain body temperature in response to cold 
and to maintain energy balance following excess caloric intake (Himms-Hagen et al.,
1994). Genetic deletion of BAT in mice results in obesity from an increase in metabolic 
efficiency (Lowell et al., 1993). In addition, expression of the Ucpl gene in white 
adipose tissue (WAT) results in a decrease in white adipose tissue mass and resistance to 
obesity (Kopecky et al., 1996). It has also been shown that Ucpl expression can be 
increased in response to dietary fat challenge and suggests that a high fat diet selectively 
regulates Ucpl expression in BAT (Surwit et al., 1998). Collectively, these studies 
indicate that Ucpl gene expression is critical in terms of energy balance and therefore 
obesity.
1.1 Ucpl Gene Regulation
Non-shivering thermogenesis is primarily regulated through increased transcription of 
Ucpl and activation of the UCP1 protein in response to cold stress. Norepinephrine 
binds to Pi and P3 adrenergic receptors on the brown fat cell surface and results in an 
increase in intracellular cyclic AMP (cAMP) which leads to an increase in the 
transcription of Ucpl. Three mechanisms are responsible for the rapid increase in levels 
of Ucpl mRNA in cold exposed rodents: an increase in the rate of initiation of Ucpl
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transcription, an increase in the fraction of Ucpl transcripts that undergo elongation, and 
stabilization of the mature Ucpl mRNA (Rehnmark et al., 1992).
In this study, we investigated the regulation of Ucpl mRNA transcription. Other studies 
have shown that regulatory elements needed for tissue-specific and cold induced Ucpl 
expression are located within -2.8 kb of the mouse Ucpl gene (Boyer and Kozak, 1991). 
To define the regulatory regions that influence Ucpl expression, Boyer and Kozak 
generated a transgenic minigene (missing exons three, four and five) with 3 kb of 5’ 
flanking DNA and 300 bp of 3’ flanking DNA, known as Ucpligl. Their work 
determined that the regulatory elements required for tissue-specificity and cold 
inducibility of the endogenous Ucpl gene were present in the Ucpltgl minigene. From 
the Ucpltgl construct, they deleted 1.8 kb from the 5’ end of Ucpltgl creating Ucpltgl 
(Figure 1). This deletion resulted in the loss of expression of the Ucpltg2 minigene in 
BAT, suggesting that there are essential regulatory elements between -3,000 and -1,200 
bp of the 5’ flanking DNA of Ucpl (Boyer and Kozak, 1991). Additional studies using 
transgenic rats have shown that regulatory elements needed for tissue-specific and cold 
induced Ucpl expression are located within -4.5 kb of the 5’ flanking region of the rat 
Ucpl gene (Cassard-Doulcier et al., 1993). In the same study, chloramphenicol acetyl 
transferase (CAT) reporter assays were used to test the activity of the Ucpl promoter and 
enhancer regions and revealed several cAMP response elements within the -4.5 kb 
flanking DNA of the rat Ucpl gene. Cyclic AMP response elements (CRE) of the rat 
Ucpl gene are located at -4,218, -3,639, -2,512, -2,122, -1,850, -1,064 and -158 bp.
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Boyer and Kozak also identified four CRE’s in the 5’ flanking DNA of the mouse Ucpl 
gene. Cassard-Doulcier et al. (1994) also revealed regulatory elements including an 
enhancer region at -2.3 kb, a minimal promoter at -157 bp, and a potential suppressor 
between -400 and -157 bp. DNase 1 footprinting of the enhancer region of the rat Ucpl 
gene revealed two domains at -2,444 to -2,423 bp and -2,352 to -2,319 bp. The first 
domain was shown to bind the retinoid X and triiodothyronine (T3) receptors and the 
second was shown to cooperatively bind nuclear factor-1 (NF-1) and Etsl (Cassard- 
Doulcier et al., 1994). Five additional footprints were reported in the 5’ flanking region 
and include: region A, -509 to -472 bp corresponding to a repeated CACCC box; region 
B, -403 to -350 bp corresponding to a protein related to Estl; region C, -182 to -159 bp 
corresponding to a protein related to NF-1; region D, -147 to -120 bp which is able to 
bind in vitro proteins related to a cAMP response element-binding protein; and region E, 
-111 to -85 bp which binds Spl in vitro (Cassard-Doulcier et al., 1994). Another study 
investigating the direct effects of T3 stimulation of the Ucpl gene in rats demonstrated 
that the thyroid hormone response sequence between -2,317 and -2,399 bp contains 
thyroid hormone response elements (TRE), which directly stimulate Ucpl (Rabelo et al.,
1995).
Kozak et al. (1994) identified a 220 bp enhancer region in the 5’ flanking region of the 
mouse Ucpl gene. In this region, they identified brown fat regulatory elements (BRE), 
which are important for tissue-specific expression and necessary for cAMP 
responsiveness. In addition, they defined two cAMP response elements; one near the
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promoter and one further upstream. The upstream CRE3 element accounted for the 
responsiveness to cAMP and BRE1 v/as essential for the function of the CRE (Kozak et 
al., 1994).
In vivo footprinting of the 5’ flanking region of Ucpl identified several potential 
regulatory regions and nuclear factors that may control the tissue-specific and cold 
inducible expression of Ucpl (Chen, 1996). The promoter region, which extends from 
the transcriptional start site to -272 bp, contains a CRE4 footprint at both -134 and -136 
bp and a potential nuclear factor-1 response element at -166 bp. A 220 bp enhancer 
region located between -2,380 and -2,600 bp contains a footprint at a CRE3 site located at 
-2,563 and -2,555 bp, a peroxisome proliferator-activated receptor y (PPARy) footprint 
located at -2,534 and -2,539 bp, a previously unidentified CCAAT enhancer binding 
protein (C/EBP) footprint located at -2,432 bp and a TRE footprint located at -2,397 bp 
(Chen, 1996). In summary, the in vivo DNase 1 footprinting experiments performed by 
Chen (1996) identified several footprints that confirmed previously observed nuclear 
factors and elucidated two novel footprints that were not previously identified, namely 
NF-1 and C/EBP (Figure 2).
1.2 Current Research
In order to further define the control of Ucpl transcription, the current study characterized 
the physiological significance of several protein-DNA binding motifs, the 5’ flanking 
DNA of Ucpl, and the previously identified DNA binding motifs in the 5’ flanking 
region of Ucpl. We utilized both in vitro and in vivo techniques to elucidate the
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regulatory regions and nuclear factors that are critical for expression of this gene. 
Functional analysis of in vivo footprinted protein-DNA interaction sites was performed by 
creating several transgenic mouse lines (Figure 1). The Ucpltg3A and3 2 line had a 
mutation in the potential NF-1 binding site located in the promoter region. The U cpf%A 
line contained a deletion in the proposed enhancer region, -2,581 to -2,335 bp. The 
Ucplig6 line contained a deletion of the proposed silencer region, -272 to -900 bp. These 
transgenic mice were designed in order to answer three questions: (i) Will deletions 
within protein-DNA binding motifs or regulatory regions eliminate transcription of Ucpl 
in BAT of cold exposed (CE) mice? (ii) Do these deletions allow Ucpl to be expressed 
in mice adapted to thermoneutrality? (iii) Do these deletions result in expression of Ucpl 
in tissues other than BAT?
We used gel shift analyses of the promoter and enhancer regions of Ucpl to determine if 
the in vivo footprints of these regions correspond to actively bound tissue-specific nuclear 
factors. Oligonucleotides were synthesized to correspond to the footprints previously 
found through in vivo footprinting of the 5’ untranslated flanking sequence of the Ucpl 
gene (Chen, 1996). Nuclear extracts were prepared from several different tissues in order 
to elucidate the tissue-specificity of potential DNA binding motifs in the promoter and 
enhancer region that were represented by the synthesized oligonucleotides (Table 1). Gel 
shift assays were performed on these oligonucleotides to determine the affinity of cold 
exposed brain, cold exposed liver, cold exposed BAT, and thermoneutral (TN) BAT 
nuclear extracts to the following in vivo footprinted sites: CRE3, PPARy, CRE2, C/EBP,
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TRE and BRE2 in the enhancer region, and NF-1 and CRE4 in the promoter region. In 
order to further define two of the footprinted regions, corresponding to nuclear factor- 1 
(NF-1) and CCAAT enhancer binding protein (C/EBP), we performed additional gel shift 
assays utilizing specific antibodies and oligonucleotides. These experiments were aimed 
at characterization of the sequence elements that the nuclear factors were binding in the 
gel shift assay.
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2. Materials and Methods
2.1 Animal Treatment
Balb/cByJ and transgenic mice were housed at room temperature and given Purina 
Rodent Chow and water ad libitum. To minimize transcription of the endogenous Ucpl 
gene and the transgene, mice were housed at 29°C for three days. These mice are referred 
to as thermoneutral (TN) adapted mice. To maximize Ucpl transcription, TN adapted 
mice were exposed individually to 4°C for one hour in pre-cooled cages with minimal 
bedding (to prevent huddling and maximize cold exposure). This has been shown to 
result in maximal transcription of Ucpl (Rehnmark et al., 1992). These mice are referred 
to as cold exposed (CE). Mice were sacrificed by cervical dislocation and tissue samples 
were either frozen in liquid nitrogen or processed immediately. For investigations of 
tissue-specific mRNA detection by northern analysis, transgenic mice were exposed to 
4°C for 24 hours in separate cages with minimal bedding to maximize Ucpl mRNA 
levels.
2.2 RNA Isolation and Northern Blot Analysis
Total RNA was prepared using the guanidinium isothiocyanate extraction method 
(Chomczynski and Sacchi, 1987) or with Tri reagent (Sigma). RNA was separated by 
formaldehyde fractionation gel electrophoresis and blotted onto Hybond N+ (Amersham) 
membrane as described by the manufacturer. The probes for northern blotting were 
prepared as a Pstl/Kpnl restriction digest of plasmid DNA containing a 500 bp fragment 
of the Ucpl gene and was labeled with [32P] dCTP by random prime labeling (Boehringer
Mannheim). To monitor total RNA loading consistency, the northern blots were reprobed 
with a BamHI/EcoRI restriction fragment derived from the mouse 18S rRNA gene 
(Bowman et al., 1981).
2.3 Nuclear Extract Isolation and Gel Mobility Shift Assay
Nuclear extract was isolated from interscapular BAT of CE and TN mice and from the 
liver and brain of CE mice. Tissues were removed and flash frozen in liquid nitrogen 
then ground utilizing a mortar and pestle and transferred to a homogenizer with a 
homogenization buffer: 10 mM HEPES, pH 7.6; 15 mM KC1; 0.15 mM Spermine; 0.5 
mM Spermidine; 1 mM EDTA; 20 mM Na2HP04, pH 7.2; 5 mM NaF; 0.2 mM (NH4)6
Mo? 0 24; 0.5 mM DTT; and 0.2 mM PMSF. The homogenate was centrifuged at 500 X g
at 0°C for five minutes. The resulting nuclei were lysed for 20 minutes on ice in a buffer 
containing: 20 mM HEPES, pH 7.6; 25% glycerol; 420 mM NaCl; 1.5 mM MgCl2; 0.2 
mM EDTA; 20 mM Na2HP04, pH 7.2; 5 mM NaF; 0.2 mM(NH4)6 Mo? 0 24; 0.5 mM
DTT; and 0.2 mM PMSF. Samples were stored in liquid nitrogen. Gel shift analysis was 
performed as described by Boyer and Kozak (1991). Synthetic oligonucleotides were 
synthesized with 5’ overhangs by DNagency (Table 1) and were labeled with [32P] dCTP 
by end filling with Klenow polymerase (New England Biolabs).
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3. Results
3.1 Cold Exposed and Tissue-specific Northern Blot Analysis of Transgenic Lines
A map of the transgenic constructs we developed can be seen in Figure 1. The first and 
second transgenes were created by Boyer and Kozak (1991) to identify tissue-specific and 
cold inducible regulatory regions. Ucpltg] contains 3 kb of the 5’ flanking untranslated 
DNA and 300 bp of the 3’ flanking DNA. In order to distinguish between the 
endogenous mouse Ucpl gene and the transgene for northern and Southern blot analysis, 
exons three, four and five were removed to make the UcpltgX minigene (Boyer and 
Kozak, 1991). The regulatory elements required for tissue-specific and cold inducible 
expression of the endogenous Ucpl gene are present in the UcpligX transgene.
Subsequent deletions described in this thesis were generated from the UcpllgX construct 
and therefore, the original UcpltgX transgene serves as our positive control. As shown in 
Figure 3, the nontransgenic Balb/cByJ mice have only one band corresponding to the 
endogenous Ucpl mRNA present in the CE BAT. In contrast, the positive transgenic 
shows two bands: the higher molecular weight band corresponds to the Ucpl mRNA and 
the lower molecular weight band corresponds to the Ucpltgl transgene mRNA. Tissue- 
specific analysis of the UcpltgX transgene mRNA reveals that the transgene is only 
expressed in BAT, similar to the expression pattern of the endogenous gene (Figure 4). 
We compared expression of the remaining transgenic constructs to the expression of the 
UcpligX transgene (Figures 3 and 4). From the Ucpltgl construct, a deletion of 1.8 kb 
from the 5’ end of UcpltgX created Ucpligl (Figure 1). This deletion resulted in total loss
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of expression of the UcplXg2 minigene in BAT (Boyer and Kozak, 1991).
Ucpllg3A and Ucpllgi l were created by introducing a mutation into the Ucpl promoter 
region corresponding to the previously identified NF-1 DNA binding motif, using the 
Clonetech site-directed mutagenesis kit. Although these are the same mutations, these 
lines are derived from different founder mice. This mutation, located at -166 to -163 bp, 
changed the endogenous Ucpl sequence from GGC to TTA. Previous research has 
shown that this simple three base pair mutagenisis results in the complete loss of NF-1 
binding (Mermod et al., 1989). Mutation in this region of the promoter of the Ucpltg3A and 
3 2 transgenes resulted in no changes in expression of either Ucpltg3A or Ucptg3'2; there is 
still expression of the minigenes in the CE BAT (Figure 5 and 6 ). Analysis of the tissue- 
specific expression of the Ucpltg3 2 minigene revealed that the transgene is expressed only 
in BAT (Figure 7).
Ucpltg4 was made by removing 246 bp from the enhancer region of Ucp!lgl (Figure 1). 
Using the Clonetech site-directed mutagenesis kit, Mlu I restriction enzyme sites were 
generated at -2,581 and -2,335 bp from the transcription start site, then the 244 bp 
fragment was removed with a Mlu I digestion and the remaining DNA was self-ligated. 
We observed a complete loss of transgene expression and only the endogenous gene can 
be observed in CE BAT (Figure 8). These results demonstrate that the 246 bp deletion in 
the enhancer region completely eliminates the expression of the Ucpltg4 construct. This 
finding was supported by the tissue-specificity northern blot, which shows that only the 
endogenous Ucpl is expressed in CE BAT while Ucpltg4 is not expressed (Figure 9).
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Analysis of Ucpltg6, the minigene with the proposed silencer deletion is shown in Figures 
10 and 11. This transgenic line was created using the Clonetech site-directed 
mutagenesis kit, through the introduction of Mlu I sites at -991 and -230 bp from the 
transcription start site. This 760 bp fragment was removed via Mlu I digestion and the 
DNA was self-ligated. Figure 10 shows that Ucpltg6 transgenic animals did not express 
the transgene differently than the endogenous Ucpl (Figure 3). The tissue-specificity blot 
shows Ucpltg6 was expressed exclusively in BAT (Figure 11).
3.2 Analysis of the Gel Shifts from the Enhancer Region
In vitro gel shift assays were conducted in order to characterize nuclear factors that bound 
the in vivo footprinted regions found by Chen (1996). All gel shifts were carried out with 
the same preparations of nuclear extracts isolated from BAT, liver and brain. Ten jag of 
corresponding nuclear extract were added per lane. All competition reactions contained 
200-fold molar excess unlabeled oligonucleotide. All probes and competitors used in the 
gel shifts are shown in Table 1.
Figure 12 shows a gel shift assay using an oligonucleotide derived from a section of the 
enhancer that contains the hypersensitivity site that corresponds to CRE3 (-2,586 to - 
2,547 bp; GSAP1). All nuclear extracts produced a single shift, 200-fold molar excess 
unlabeled GSAE1 resulted in a partial competition with the labeled probe. The strongest 
shift was produced with CE liver extract followed by TN BAT and CE brain extract and 
the weakest shift was produced by CE BAT. A shift indicates that a nuclear factor has 
bound the oligonucleotide and has retarded its migration through the gel matrix during
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electrophoresis.
Figure 13 represents a gel shift assay using GSAE2, a section of the enhancer region 
between -2,552 and -2,513 bp that contains the hypersensitivity site to PPARy and CRE2. 
All of the extracts produced shifts. The strongest was produced by CE liver extract 
followed by extract obtained from TN BAT. CE BAT extract was the next strongest shift 
followed by CE brain extract, which produced two shifts. All shifts were partially 
removed with the addition of 200-fold molar excess unlabeled GSAE2.
Figure 14 is a gel shift assay of the GSAE3 oligonucleotide probe containing -2,450 to - 
2,411 bp of Ucpl, a region of the enhancer corresponding to the binding site of C/EBP. 
We observed that TN BAT extract resulted in the strongest shift followed by CE liver 
extract and then CE BAT extract. CE brain extract showed a very weak shift. All 
competitions, with 200-fold molar excess unlabeled GSAE3, resulted in partial or 
complete removal of the bands.
The competition assay using GSAE4, a region of the enhancer that correlates to the 
hypersensitivity sites for TRE and BRE2 (-2,416 to -2,377 bp), is shown in 
Figure 15. The strongest shift was seen in CE brain, followed by CE liver then TN BAT. 
The weakest shift occurred with CE BAT. Two hundred-fold molar excess unlabeled 
GSAE4 resulted in complete removal of the shifts.
Figure 16 is a competition assay that corresponds to the suspected C/EBP hypersensitivity 
site of the enhancer found by Chen (1996). The negative control contains labeled GSAE3 
without nuclear extract. The positive control contains labeled GSAE3 with CE BAT
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extract and resulted in two shifts. All the remaining lanes contain 10 jag of CE BAT 
extract and competitors or antibodies. The third lane shows the effect of the addition of 
200-fold molar excess unlabeled GSAE3, which resulted in the partial removal of the 
higher molecular weight band while the lower molecular weight band is almost 
completely removed. To further characterize the proteins that are binding GSAE3, we 
competed the shift in the third lane with a mutated C/EBP binding motif in the GSAE3 
oligonucleotide (mC/EBP). Although a return of the shift was expected, we observed 
only a partial competition of the lower band. The fifth lane shows that when competed 
with a consensus C/EBP oligonucleotide, no competition was observed. With the 
addition of C/EBP antibodies a, p and 8 in the sixth, seventh and eighth lanes, 
respectively, no supershifts were observed, suggesting that C/EBP proteins were not 
binding to the GSAE3 oligonucleotide. The ninth and tenth lanes correspond to GSAE3 
that has been mutated on either the right or left flanking regions of the suspected 
hypersensitivity site of C/EBP (Table 1). We observed that no competition occurred in 
GSAE3mR, but the lower band is removed with the 200-fold addition of GSAE3mL, 
suggesting that proteins interacted with the right half of the oligonucleotide flanking the 
C/EBP hypersensitivity site.
3.3 Analysis of the Gel Shifts from the Promoter Region
Figure 17 is a competition assay of the probe GSAP1, a section of the promoter region 
that corresponds to the NF-1 DNA binding site. Nuclear extracts from several tissues 
bound to the GSAP1 oligonucleotide. The strongest shift was observed with CE liver
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extract, followed by the CE BAT extract, then the TN BAT extract and lastly the CE 
brain extract. Addition of 200-fold molar excess competitor DNA (unlabeled GSAP2) 
resulted in minimal removal of the shifts.
A gel shift assay using the probe GSAP2 is shown in Figure 18. This region of the 
promoter corresponds to the CRE4 binding site and resulted in strong shifts from all 
nuclear extracts. Two-hundred fold molar excess unlabeled GSAP2 partially removed the 
shifts.
Figure 19 is a competition assay of GSAP1, which corresponds to the NF-1 DNA binding 
motif in the promoter region found by Chen (1996). The negative control, the first lane, 
consists of labeled GSAP1 without nuclear extract. The second lane, the positive control, 
consists of labeled GSAP1 with 10 |j,g CE BAT extract. The remaining lanes contain 10 
(a.g CE BAT extract and 200-fold molar excess unlabeled competitors or NF-1 antibody. 
The third lane contains unlabeled GSAP1, which competes the shift away, however, DNA 
with a mutation of the hypersensitivity sight in the NF-1 binding motif (mGSAPl) also 
competed the shift. Competition with NF-1 antibody resulted in no supershift.
GSAPlmR and GSAPlmL are sequences that have mutated flanking regions around the 
NF-1 hypersensitivity site. Only the GSAPlmR competitor resulted in a decrease in the 
intensity of the shift.
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4. Discussion
4.1 C/EBP and NF-1 Effects on Ucpl Expression
NF-1 has been implicated in regulation of adipocyte specific genes (Graves et al., 1991). 
Although in vivo footprinting suggests that nuclear factors are binding the Ucpl promoter 
(Chen 1996), gel shift analysis failed to confirm that NF-1 or other specific protein-DNA 
interactions were binding to the region between -166 and -163 bp. In support of the gel 
shift assays in this region (Figure 12), analysis of the transgenic line Ucpltg3, containing a 
deletion of the NF-1 DNA binding motif, between -166 and -163 bp, results in normal 
tissue-specific and cold inducible expression of the Ucpl gene and suggests that this NF- 
1 binding motif is not involved in the regulation of Ucpl in vivo. It is possible that a 
protein containing a binding motif similar to NF-1 is interacting with our oligonucleotide 
and binding to the flanking region extending to the right of the NF-1 binding motif 
resulting in the hypersensitivity site and in vitro gel shifting. It is also possible that the 
binding is non-specific, because of the inability of competitors to remove the shift.
The C/EBP family of transcription factors has been associated with both the 
differentiation of BAT from preadipocytes (Darlington et al., 1998) and the expression of 
Ucpl (Manchado et al., 1994). The C/EBP family has many isoforms that are present in 
several tissue types. Moreover, it has been shown that C/EBPp, but not C/EBPa, is 
increased in rat BAT after one hour of cold exposure, at both transcriptional and 
translational levels (Yubero et al., 1994), suggesting that the C/EBP family of proteins is 
tightly coupled with Ucpl regulation.
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Following the identification of the in vivo footprint occurring at a C/EBP binding motif 
located between -2,450 and -2,411 bp, we performed a gel shift competition assay with a 
labeled oligonucleotide from this region, GSAE3 (Figure 16). Although C/EBP has 
previously been implicated in the control of Ucpl gene expression, our results do not 
strongly support the idea that this region of the enhancer contains a functional C/EBP 
binding site (Figure 16).
4.2 Nuclear Factors Bind to Additional Footprinted Regions In vitro
To determine whether nuclear factors bound to the additional sites previously identified 
through in vivo footprinting (CRE’s, PPARy and TRE) (Figure 2), we performed in vitro 
gel shift analyses with nuclear extracts derived from CE BAT, CE liver, CE brain and TN 
BAT. All of the nuclear extracts exhibited protein-DNA interactions, suggesting that 
these protein-DNA binding motifs may be important regulatory sequences for Ucpl 
expression (Figures 12-19). Figure 12 represents a gel shift analysis of the enhancer 
region between -2,586 and -2,547 bp, containing the CRE3 binding motif. All of the 
nuclear extracts bound rather weakly to the oligonucleotide probe. While it is not 
surprising that protein-DNA interactions were observed in several tissues due to the 
involvement of c/AMP in many tissues for several different functions, the relative degree 
of binding in the TN BAT extract was not expected because thermoneutrality is known to 
repress Ucpl transcription. Figure 13 represents a gel shift assay of the enhancer region 
between -2,552 and -2,513 bp of the Ucpl gene. This region of the enhancer contained 
previously identified DNA binding motifs for PPARy and CRE2. Nuclear extracts from
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all tissues tested produced diffuse gel shifts and the addition of CE brain extract produced 
two shifts. All of these protein-DNA interactions were partially competed by the 
addition of 200-fold excess unlabeled probe, suggesting that these protein-DNA 
interactions are specific to the probe. Figure 14 represents another gel shift assay in the 
enhancer region between -2,450 and -2,411 bp and contains a C/EBP binding site. All of 
the nuclear extracts again produced a diffuse band shift, despite repeated attempts to 
change the DNA binding conditions and the gel electrophoresis parameters. Liver 
nuclear extract produced the strongest shift and the weakest shift was observed using 
brain nuclear extract, consistent with the known pattern of C/EBP. A gel shift assay of 
the region between -2,416 and -2,377 bp is shown in Figure 15. The oligonucleotide 
probe used in this assay contains TRE and BRE2 DNA binding motifs observed 
previously and in our in vivo footprints. The resulting shifts are weak, but do suggest that 
this region binds nuclear proteins. Figure 17 represents a gel shift assay of region -184 to 
-145 bp of the promoter region of Ucpl. All of the extracts contain nuclear proteins 
which shifted the labeled oligonucleotide probe, but the addition of 2 0 0 -fold excess 
unlabeled GSAP1 resulted in no removal of the shifts. This suggests that the binding of 
nuclear proteins in this region is non-specific. Figure 18 illustrates a gel shift of the 
promoter region between -164 to -125 bp. The oligonucleotide that we synthesized, 
GSAP2, contains the sequence located within an in vivo footprint that corresponds to the 
CRE4 DNA binding motif. All extracts produced a shift and the addition of 200-fold 
excess GSAP2 resulted in partial removal of the shifts. This suggests that the binding of
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proteins to this region of the promoter is specific and that this region may be important to 
Ucpl expression.
4.3 Transgenic Analysis of the Promoter, Enhancer and Silencer Regions
We analyzed the transcriptional control of Ucpl through mutation analysis of several 
upstream untranslated regions. Mutated minigene constructs microinjected to generate 
transgenic mice and positive transgenic founders were crossed with Balb/cByJ +/+ mice 
to generate Fi offspring. Expression of the transgenes was examined for tissue-specificity 
and cold inducible expression by northern analysis. The experiments were designed to 
answer three questions: (i) Will specific regulatory region deletions eliminate 
transcription of Ucpl in BAT of cold exposed mice? (ii) Do specific regulatory region 
deletions result in the Ucpl transgene constructs expression in mice adapted to 
thermoneutrality? (iii) Do any of these deletions result in expression of Ucpl in tissues 
other than BAT?
Transgenic evaluation of the NF-1 DNA binding site in the promoter region of Ucpl 
(Ucpltg3A and Ucplt%32), resulted in no discemable differences in cold inducible or tissue- 
specific expression of the transgene compared to the endogenous gene (Figures 5, 6 and 
7). These results were somewhat surprising since our laboratory previously observed 
cold-inducible in vivo footprints in this region (Chen, 1996). Our transgenic results 
therefore suggest that the 5’ flanking DNA of Ucpl, between -166 to -163 bp, 
corresponding to the NF-1 hypersensitivity site of the Ucpl promoter is not required for 
cold inducible or tissue-specific expression of Ucpl.
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Analysis of the minigene containing a deletion in the enhancer region (-2.5 to -2.3 kb, 
Ucpllg4), resulted in the complete loss of expression. This data supports the data of 
Kozak et al. (1994), suggesting that regulatory elements in the region located between -
2,335 and -2,581 bp are critical for the expression of Ucpl.
Analysis of transgenic mice containing the minigene with the deletion of the proposed 
silencer region (between -991 and -230 bp, Ucpltg6), resulted in a tissue-specific and cold 
inducible expression no different from that observed for the endogenous Ucpl gene. The 
data from the Ucplt%6 northern analysis is not consistent with results of Kozak et al. 
(1994), who found that this region of DNA was associated with strong repression of Ucpl 
expression in cell culture. We initially hypothesized that this negative regulatory 
sequence could be responsible for the tissue-specific expression of Ucpl, and that 
through deletion of this element, we might see broader tissue distribution of Ucpl. 
However, our results demonstrate that this sequence is not involved in BAT-specific 
expression or at least it does not act alone in limiting expression of Ucpl to BAT.
Our studies involving transgenic mice further refine the model of Ucpl expression. We 
know from previous work, that U cpf%x (containing 3 kb of 5’flanking DNA) has the 
regulatory elements required for tissue-specific and cold inducible expression of the 
minigene. Moreover, Ucpltg2 (containing 1.2 kb of 5’ flanking DNA) results in no 
expression in BAT of cold exposed mice (Boyer and Kozak, 1991). This experiment 
suggested that there are important regulatory sequences between -3,000 and -1,200 bp.
We have now refined this regulatory region to elements located between -2,581 and -
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2,335 bp, which have previously been predicted to be critical for tissue-specific and cold 
inducible expression of Ucpl (Figure 8 and 9). We have shown that this region has 
several potential regulatory regions where nuclear factor binding motifs can be found, 
namely CRE3, PPARy, CRE2, TRE, BRE2, and C/EBP (Chen, 1996). The region 
previously suspected of having silencer elements, between -991 and -230 bp, has no 
apparent effect on the expression of Ucpl in regards to tissue-specificity or cold 
adaptability (Figures 10 and 11). In addition, footprinting analysis implied a NF-1 
hypersensitivity site located in the promoter region (Chen, 1996). Our work with 
£/cpitg31 and Ucplt%3 2 (Figure 5-7 and 19) show that -166 to -163 bp of the promoter 
region is not required for expression of Ucpl and that the protein that is binding to this 
section of the promoter is not conclusively NF-1.
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Table 1. List of oligonucleotides used in gel shift analysis
GSAE1
-2586 CRE3 -2547
TGAAGCTTGCTGTCACTCCTCTACAGCGTCACAGAGGGGTC 
GSAE2
-2552 PPARv CRE2 -2513
AGGGTCAGTCACCCTTGACCACACTGAACTAGTCGTCACC 
GSAE3
-2450  C/EBP_______  -2411
ACTGCTCTCTCCATTTATGAGGCAAACTTTCTTTCACTTCC 
mGSAE3 (mutated C/EBP site, but same flanking region as GSAE3) 
ACTGCTCTCTCCATTACCTATTGCGCTTTCTTTCACTTCC 
GSAE3mR (flanking region mutated right of C/EBP site) 
ACTGCTCTCTCCATTATGAGGCAAATCCCTCCCTGTGCTC 
GSAE3ML (flanking region mutated left of C/EBP site)
GT CAT CTCTCTTTCCGT G AGGC AA ACTTT CTTT C AC CTC G 
C/EBP (consensus C/EBP from Shuman et al., Science V. 249 p 774, 1990.) 
T GC AG ATT GCGC A AT C 
GSAE4
-2416  IR E_______  BRE2-2377
ACTTCC AGAGGCTCTGGGGGC AGC AAGGT C AACCCTTTCC 
GSAP1
-184 ____________ NF-1_________  -145
CCAAATCAGAGGTGATGTGGCCAGGGCTTTGGGAGTGACG 
mGSAPl (mutated NF-1 site, but same flanking region as GSAP1)
CCA A AT C AG AGGT GAT GTTTAC AGGGCTTT GGGAGT G ACG 
GSAPlmL (flanking region mutated left of NF-1 site) 
TTGGGCTGAGAACAGCACGGCCAGGGCTTTGGGAGTTACC 
GSAPlmR (flanking region mutated right of NF-1 site) 
CCAAATCAGAGGTGATGTGGCTGAAATCCCAAAGACCCCC 
NF-1 (consensus NF-1 from Mermod et al., 1989)
T GGCGCT ATTTT GG ATT G AAGCC A AT AT G ACC GGC AT AGT 
GSAP2
-164 CRE4 -125
CAGGGCTTTGGGAGTGACGCGCGGCTGGGAGGCTTGCGC
• GSA = Gel Shift Analysis
• P = the Promoter region
• E = the Enhancer region
All of the probes were double stranded (only the top strand is shown) and 5’ overhangs 
were end filled with Klenow. The underlined segments indicate the closest match to the 
consensus sequence for the nuclear factors that are located above the underlined 
sequences. All GSA probes are oligonucleotides synthesized for the purpose of in vitro 
analysis of footprinted regions.
Table 2. Abbreviation list
BAT brown adipose tissue
BRE brown fat regulatory elements
C/EBP CCAAT enhancer binding protein
cAMP cyclic AMP
CE cold exposed
CRE cAMP response elements
GSAE gel shift assay, enhancer
GSAP gel shift assay, promoter
NF-1 nuclear factor- 1
PPARy peroxisome proliferator-activated receptor y
TN thermoneutral
TRE thyroid hormone response elements
Ucpl Uncoupling protein 1 gene
UCP1 Uncoupling protein 1 protein
WAT white adipose tissue
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-3 kb Exons
Ucpl1?1 Enhancer Silencer Promoter
-1.2 kb
Ucpl*2 Silencer Promoter
Ucpl*3-1
and
Ucpl*32
-166 bp to -163 bp
GGC cj>TTA (NF-1)
-2,581 bp -2,335 bp
Ucpl*4
-991 bp -230 bp
Ucpl*6
Figure 1. A map of the transgenic constructs. Ucpli%x is the endogenous 3 kb of 5’ 
flanking DNA and therefore our control. Numbered boxes represent exons.
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Figure 2. Map of in vivo footprinting performed by Chen, 1996.
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Figure 3. Cold exposed northern blot analysis of Ucpli%x mRNA. Twenty jag total RNA 
were loaded per lane. Thermoneutral mice were acclimated to 29°C for three days. Cold 
exposed mice were thermoneutral acclimated to 29°C for three days and then exposed to 
4°C for one hour. Loading differences between lanes were resolved by normalization 
with a probe for the 18S RNA subunit (as shown below). Symbols: + indicates a 
transgenic mouse, - indicates a non-transgenic mouse.
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Figure 4. Tissue-specificity northern blot analysis of Ucpltgl mRNA. Twenty p.g total 
RNA were loaded per lane. Maximum transcription was induced by exposing mice to 
4°C for 24 hours. Loading differences between lanes were resolved by normalization 
with a probe for the 18S RNA subunit (as shown below).
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Figure 5. Cold exposed northern blot analysis of Ucplts3A mRNA. Twenty p.g total RNA 
were loaded per lane. Thermoneutral mice were acclimated to 29°C for three days. Cold 
exposed mice were thermoneutral acclimated to 29°C for three days and then exposed to 
4°C for one hour. Loading differences between lanes were resolved by normalization 
with a probe for the 18S RNA subunit (as shown below). Symbols: + indicates a 
transgenic mouse, - indicates a non-transgenic mouse.
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Figure 6 . Cold exposed northern blot analysis of Ucpltg3 2 mRNA. Twenty (j,g total RNA 
were loaded per lane. Thermoneutral mice were acclimated to 29°C for three days. Cold 
exposed mice were thermoneutral acclimated to 29°C for three days and then exposed to 
4°C for one hour. Loading differences between lanes were resolved by normalization 
with a probe for the 18S RNA subunit (as shown below). Symbols: + indicates a 
transgenic mouse, - indicates a non-transgenic mouse.
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Figure 7. Tissue-specificity northern blot analysis of Ucpltg3 2 mRNA. Twenty |ag total 
RNA were loaded per lane. Maximum transcription was induced by exposing mice to 
4°C for 24 hours. Loading differences between lanes were resolved by normalization 
with a probe for the 18S RNA subunit (as shown below).
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Figure 8 . Cold exposed northern blot analysis of Ucpltg4 mRNA. Twenty (j,g total RNA 
were loaded per lane. Thermoneutral mice were acclimated to 29°C for three days. Cold 
exposed mice were thermoneutral acclimated to 29°C for three days and then exposed to 
4°C for one hour. Loading differences between lanes were resolved by normalization 
with a probe for the 18S RNA subunit (as shown below). Symbols: + indicates a 
transgenic mouse, - indicates a non-transgenic mouse.
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Figure 9. Tissue-specificity northern blot analysis of Ucpltg4 mRNA. Twenty |ag total 
RNA were loaded per lane. Maximum transcription was induced by exposing mice to 
4°C for 24 hours. Loading differences between lanes were resolved by normalization 
with a probe for the 18S RNA subunit (as shown below).
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Figure 10. Cold exposed northern blot analysis of Ucpll%6 mRNA. Twenty |ag total RNA 
were loaded per lane. Thermoneutral mice were acclimated to 29°C for three days. Cold 
exposed mice were thermoneutral acclimated to 29°C for three days and then exposed to 
4°C for one hour. Loading differences between lanes were resolved by normalization 
with a probe for the 18S RNA subunit (as shown below). Symbols: + indicates a 
transgenic mouse, - indicates a non-transgenic mouse.
Figure 11. Tissue-specificity northern blot analysis of Ucpltg6 mRNA. Twenty |j,g total 
RNA was loaded per lane. Maximum transcription was induced by exposing mice to 4°C 
for 24 hours. Loading differences between lanes were resolved by normalization with a 
probe for the 18S RNA subunit (as shown below).
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Figure 12. Gel shift assay of the enhancer region between -2,586 and -2,547 bp. Control
lane is labeled probe without nuclear extract. Competitor was 200-fold excess unlabeled
probe (GSAE1).
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Figure 13. Gel shift assay of the enhancer region between -2,552 and -2,513 bp. Control
lane is labeled probe without nuclear extract. Competitor was 200-fold excess unlabeled
probe (GSAE2).
Figure 14. Gel shift assay of the enhancer region between -2,450 and -2,411 bp. Control
lane is labeled probe without nuclear extract. Competitor was 200-fold excess unlabeled
probe (GSAE3).
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Figure 15. Gel shift assay of the enhancer region between -2,416 and -2,377 bp. Control
lane is labeled probe without nuclear extract. Competitor was 200-fold excess unlabeled
probe (GSAE4).
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Figure 16. Gel shift competition assay of C/EBP. Probe used was GSAE3. Nuclear extract 
is CE BAT. Negative control lane is labeled probe without nuclear extract. Positive control 
is the labeled probe with nuclear extract. Competitors were unlabeled probes added in 200- 
fold molar excess. Lanes with antibodies do not contain competitors.
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Figure 17. Gel shift assay of the promoter region between -184 and -145 bp. Control lane is
labeled probe without nuclear extract. Competitor was 200-fold excess unlabeled probe
(GSAP1).
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Figure 18. Gel shift assay of the promoter region between -164 and -125 bp. Control lane is
labeled probe without nuclear extract. Competitor was 200-fold excess unlabeled probe
(GSAP2).
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Figure 19. Gel shift competition assay of NF-1. Probe used was GSAP1. Nuclear extract is 
CE BAT. Negative control lane is labeled probe without nuclear extract. Positive control is 
the labeled probe with nuclear extract. Competitors were unlabeled probes added in 200-fold 
molar excess. Lanes with antibodies do not contain competitors.
